Anticoagulation following tissue aortic valve replacement

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN51663857

Enrollment

400

Registered

2006-04-10

Start date

2006-05-01

Completion date

Unknown

Last updated

2016-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic valve disease Circulatory System Aortic valve disease

Interventions

Three groups: warfarin therapy for 90 days, aspirin therapy for 90 days, control group (no medication)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing tissue aortic valve replacement

Exclusion criteria

Exclusion criteria: 1. Patients who require aspirin or warfarin therapy on established medical grounds 2. Patients unable to take warfarin or aspirin

Design outcomes

Primary

Measure	Time frame
1. Neurological events 2. Stroke	—

Secondary

Measure	Time frame
Thrombus formation	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026